# A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan

> **NCT01370148** · PHASE1 · COMPLETED · sponsor: **Cumberland Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- Liver Disease

## Interventions

- **DRUG:** conivaptan hydrochloride

## Key facts

- **NCT ID:** NCT01370148
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2014-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01370148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01370148, "A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01370148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*